

To the Shareholders of Molecular Partners AG

## Invitation to the Extraordinary General Meeting

Tuesday, October 31, 2017, 2:00 p.m. CEST (doors open at 1:00 p.m.)  
Molecular Partners AG, 5<sup>th</sup> Floor, **Wagistrasse 14, 8952 Schlieren**, Switzerland

### Agenda and Proposals of the Board of Directors

#### 1 Election of William (Bill) Burns to the Board of Directors

The Board of Directors proposes the election of William (Bill) Burns as member of the Board of Directors for a term of office until the conclusion of the 2018 annual general meeting.

##### *Explanations*

William (Bill) Burns brings to Molecular Partners a large experience in the development and commercialization of drugs, in particular in oncology, and an extensive knowledge of the pharmaceutical industry. Bill Burns worked for Roche in various positions for 28 years culminating in the position as CEO of Roche Pharmaceuticals (2001-2009) and board seats at Roche (2010-2014), Genentech (2004-2014) and Chugai Pharmaceutical (2002-2014).

Since 2010, he has been Senior Independent Non-Executive Director of Shire Pharmaceuticals from which he will step down in April 2018. Bill Burns has been Vice-Chairman of Mesoblast since 2016. He is Trustee of the Institute of Cancer Research, London and a member of the Scientific Advisory Board Member of the Center for Integrated Oncology of the University of Cologne/Bonn.

Upon his election by the extraordinary general meeting, the Board of Directors intends to appoint Bill Burns as Vice-Chairman. The Board of Directors intends to nominate Bill Burns for election as Chairman at the 2018 annual general meeting.

#### 2 Election of Patrick Amstutz to the Board of Directors

The Board of Directors proposes the election of Patrick Amstutz as member of the Board of Directors for a term of office until the conclusion of the 2018 annual general meeting.

##### *Explanations*

Patrick Amstutz has been Chief Executive Officer of Molecular Partners since November 2016. From 2014 to 2016, he was Chief Operating Officer and from 2006 to 2014, Chief Business Officer of the company. He co-founded Molecular Partners and has been a member of the Company's management team since its inception in 2004. As Chief Operating Officer and Chief Business Officer, Patrick Amstutz was responsible for business development, alliance management and research and development (R&D) operations. He has established a wide range of commercial collaborations and licensed several key technologies. Patrick Amstutz holds a Master of Science from the ETH Zurich and a PhD in Molecular Biology from the University of Zurich

The general meeting will be conducted in English.

Schlieren, October 9, 2017

Jörn Aldag, Chairman of the Board of Directors

## Organizational Information

### Location

Molecular Partners AG  
5<sup>th</sup> Floor  
Wagistrasse 14  
8952 Schlieren  
Switzerland



### Participation and Voting Rights

Shareholders registered with voting rights in the share register as of October 23, 2017, 5:00 p.m., CEST, will be authorized to participate and vote at the general meeting. They will receive their admission card and voting materials upon returning the enclosed registration form. Please use therefor the enclosed pre-addressed envelope.

### Representation and Proxy

Shareholders who do not attend the general meeting in person may be represented by another shareholder or by the independent proxy, Andreas G. Keller, Anwaltskanzlei Keller, Gehrenholzpark 2g, 8055 Zurich. Shareholders wishing such representation by the independent proxy are asked to sign the enclosed proxy form and to forward it, together with any directives, to the Company's share registrar areg.ch ag (see below). For practical reasons, the decision to be represented by the independent proxy may be revoked by the shareholder in favor of personal attendance or attendance by another shareholder no later than October 29, 2017, 11:59 p.m., CEST.

In the absence of specific instructions on the proxy form, general authorization is granted to the independent proxy to vote the shares in favor of the proposals of the Board of Directors. This also applies to proposals which were not included in this invitation and submitted during the general meeting.

### Electronic Proxy and Voting

You have also the option to issue proxies and voting instructions to the independent proxy via the Internet. Enter [www.netvote.ch/molecularpartners](http://www.netvote.ch/molecularpartners) in your browser and follow the user prompts on the display. You have the same reply options as with the paper format. You will find your personal access data (ID and password) for the initial registration on the registration form. Electronic participation and any changes to directives issued electronically may be made until October 29, 2017, 11:59 p.m., CEST.

### Entries in the Share Register – Trading of Shares

No entries will be made in the share register in the period from October 24, 2017 until the end of the extraordinary general meeting. However, shares may be traded without restrictions. Shareholders who sell part or all of their shares before the extraordinary general meeting are no longer entitled to vote to that extent. They are requested to return or to exchange their admission card and voting material.

### Future Electronic Receipt of Invitations to General Meeting

If you would like to receive invitations to general meetings electronically in the future, you can access the instruction issuance system under <https://netvote.ch/molecularpartners> and click on "Select correspondence method". The login details can be found on the enclosed reply slip.

### Questions

Please direct your administrative questions directly to our share registrar (areg.ch ag, Fabrikstrasse 10, 4614 Hägendorf, Switzerland, tel. +41 62 209 16 60, e-mail: [info@areg.ch](mailto:info@areg.ch)).